Llwytho...
Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. No...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Therap Adv Gastroenterol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622287/ https://ncbi.nlm.nih.gov/pubmed/26557893 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X15592586 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|